Intro Pullout Text Widget

RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Podcast icon Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple PodcastsGoogle Podcasts, Stitcher and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team


Current Issue

New Editor-in-Chief: Professor Gerd Burmester

BMJ and EULAR are delighted to announce that Professor Gerd Burmester has been appointed as the new Editor-in-Chief for RMD Open.


Professor Burmester was the Director of the Department of Rheumatology and Clinical Immunology at the Charité Universitätsmedizin Berlin until very recently and is now a Senior Professor at this institution. He is a former President of EULAR. Since 2017 he has been President of the Board of Trustees of the FOREUM Foundation for Research in Rheumatology.


Professor Burmester has been an active supporter of RMD Open since its inception and we're excited that he has agreed to take the journal forward into its next stage of development.


Professor Gerd Burmester

Video Abstract

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

To cite: Khanna D, Maher TM, Volkmann ER, et al. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open 2023;9:e002859. doi: 10.1136/rmdopen-2022-002859.

Read the full article here: link
Objective: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC.

Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.